KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.

Employees

3,615

Sector

Personal Products

Calendar

Jun. 26 - Détachement de for dividende intermédiaire

More about the company

Quotes

Date	Price	Change	Volume
25-06-16	5,504.00 ¥	-0.60%	304,300
25-06-13	5,537.00 ¥	-0.79%	252,600
25-06-12	5,581.00 ¥	-0.99%	267,300
25-06-11	5,637.00 ¥	+1.13%	415,400
25-06-10	5,574.00 ¥	+0.49%	352,500

Delayed Quote Japan Exchange, June 16, 2025 at 02:30 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

BBB

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5,537.00JPY

Average target price

5,567.50JPY

Spread / Average Target

+0.55%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-06-16 am EDT			5-day change	1st Jan Change
5,504.00 ^JPY	-0.60%		+1.07%	-11.65%

Jun. 12	Kobayashi Pharmaceutical Co., Ltd. Require Kazumasa Kobayashi and Akihiro Kobayashi to Resign from Their Roles as Special Advisor and Director in Charge of Compensation, Respectively	CI
Apr. 25	Kobayashi Pharmaceutical Co Ltd - Received Notice Of Lawsuit Filing From Shareholder Oasis Japan Strategic Fund	RE

Capitalization	412B 2.86B 2.47B 2.32B 2.1B 3.88B 246B 4.39B 27.12B 10.55B 113B 10.73B 10.5B	P/E ratio 2025 *	33.8x	P/E ratio 2026 *	27.9x
Enterprise value	354B 2.46B 2.12B 1.99B 1.81B 3.33B 211B 3.77B 23.29B 9.06B 96.77B 9.22B 9.02B	EV / Sales 2025 *	2.07x	EV / Sales 2026 *	1.94x
Free-Float	60.58%	Yield 2025 *	1.87%	Yield 2026 *	1.9%

Kobayashi Pharmaceutical Co., Ltd. Require Kazumasa Kobayashi and Akihiro Kobayashi to Resign from Their Roles as Special Advisor and Director in Charge of Compensation, Respectively	Jun. 12	CI
Kobayashi Pharmaceutical Co Ltd - Received Notice Of Lawsuit Filing From Shareholder Oasis Japan Strategic Fund	Apr. 25	RE
Oasis Management - Filed Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors	Apr. 06	RE
Oasis Files Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors	Apr. 06	CI
Kobayashi Pharmaceutical Co. Announces CEO Changes	Mar. 28	CI
Kobayashi Pharmaceutical Co. Announces Executive Changes	Mar. 28	CI
Declaration of Voting Results by Kobayashi Pharmaceutical	Mar. 28	CI
Oasis Management Company Issues Recommendations to Shareholders of Kobayashi Pharmaceutical	Mar. 11	CI
Oasis: Urges Shareholders To Vote Against Appointment Of Akihiro Kobayashi, Others As Directors At Kobayashi Pharma AGM	Mar. 10	RE
Oasis Management Urges Shareholders to Vote Against Kobayashi Pharmaceutical?s Directors	Mar. 10	CI
Independent Proxy Advisory Firms Supports Oasis Management Proposals	Feb. 17	CI
Glass Lewis ESG Controversy Alert: Kobayashi Pharmaceutical	Feb. 17	MT
Satoshi Yamane Will Step Down as Executive Officer of Kobayashi Pharma	Jan. 21	CI

Jefferies Adjusts Kobayashi Pharmaceutical's Price Target to 4,900 Yen From 4,800 Yen, Keeps at Underperform	Nov. 01	MT
UBS Adjusts Kobayashi Pharmaceutical's Price Target to 12,600 Yen From 13,100 Yen, Keeps at Buy	22-03-03	MT

Kobayashi Pharmaceutical Co., Ltd. Stock

Equities

4967

JP3301100008

Personal Products

Valuation: Kobayashi Pharmaceutical Co., Ltd.

Chart: Kobayashi Pharmaceutical Co., Ltd.

Latest news: Kobayashi Pharmaceutical Co., Ltd.

Analysts' recommendations: Kobayashi Pharmaceutical Co., Ltd.

Press Releases: Kobayashi Pharmaceutical Co., Ltd.

News in other languages: Kobayashi Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Kobayashi Pharmaceutical Co., Ltd.

ETFs: Kobayashi Pharmaceutical Co., Ltd.

Other Personal Products

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Voting Cards Reveal that Over 50% of Shareholders Excluding the Founding Family and Related Parties Voted For Oasis’s EGM Proposals and Against Mr. Akihiro Kobayashi’s Renomination at the AGM	Jun. 11	BU
Kobayashi Pharmaceutical : FY2025（January 1, 2025 - December 31, 2025）1Q Financial Statement	May. 08	PU
Kobayashi Pharmaceutical : Financial Overview for First Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)	May. 08	PU
Oasis Files Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors	Apr. 06	BU
Oasis Urges All Shareholders to Vote AGAINST the Appointment of Mr. Akihiro Kobayashi, Mr. Katae, Mr. Ohta and Mr. Takahashi as Directors at the Kobayashi Pharma AGM	Mar. 10	BU

Razzia bei japanischem Pharma-Konzern nach Todesfällen	24-03-31
Scandale aux compléments alimentaires au Japon: deux nouveaux décès suspects	24-03-28
Bourses asiatiques: Tokyo soutenue par la chute du yen	24-03-27
Tokyo en hausse en matinée	24-03-26

1 day	-0.60%
1 week	-0.78%
Current month	+4.48%
1 month	+4.92%
3 months	-3.61%
6 months	-8.56%
Current year	-11.65%

1 week	5,453	5,678
1 month	4,850	5,678
Current year	4,850	6,220
1 year	4,850	6,350
3 years	4,700	9,410
5 years	4,700	13,120
10 years	4,025	13,120

Manager	Title	Age	Since
Akihiro Kobayashi PSD	President	54	2013-05-31
Noriaki Hirao IRC	Investor Relations Contact	-	-
Kenji Kohori SAM	Sales & Marketing	70	-

Director	Title	Age	Since
Akihiro Kobayashi BRD	Director/Board Member	54	2004-05-31
Kunio Ito BRD	Director/Board Member	73	2013-05-31
Kaori Sasaki BRD	Director/Board Member	66	2016-05-31

Name	Weight	AuM	1st Jan change
NOMURA NEXT FUNDS TOPIX-17 RAW MATERIALS & CHEMICALS ETF - JPY	1.19%	7 M€	-6.07%	-
NEXT FUNDS MSCI JAPAN COUNTRY ESG LEADERS INDEX EXCHANGE TRADED FUND - JPY	0.21%	14 M€	-3.80%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
KOBAYASHI PHARMACEUTICAL CO., LTD.	-0.60%	-0.78%	-1.87%	-30.24%	2.86B
PROCTER & GAMBLE COMPANY	-1.78%	-2.28%	-3.90%	+20.96%	376B
UNILEVER PLC	-0.76%	-0.50%	+3.68%	+29.37%	157B
COLGATE-PALMOLIVE COMPANY	-3.09%	+0.02%	-4.61%	+21.71%	73.15B
HINDUSTAN UNILEVER LIMITED	+0.44%	-2.67%	-6.32%	+8.50%	63.28B
KENVUE INC.	-2.68%	-1.29%	+18.71%	-	41.18B
BEIERSDORF	-2.69%	-4.44%	-22.75%	+24.04%	29.44B
ESTEE LAUDER	-3.83%	-1.68%	-40.90%	-72.31%	24.21B
ESSITY AB	-1.02%	-3.58%	-3.93%	+3.89%	19.2B
GODREJ CONSUMER PRODUCTS LIMITED	-0.03%	-2.38%	-15.32%	+60.21%	14.13B
Average	-1.61%	-1.58%	-7.72%	+7.35%	80.02B
Weighted average by Cap.	-1.62%	-1.70%	-3.52%	+18.98%

	2025 *	2026 *
Net sales	170B 1.18B 1.02B 961M 871M 1.61B 102B 1.82B 11.23B 4.37B 46.66B 4.44B 4.35B	179B 1.24B 1.08B 1.01B 915M 1.69B 107B 1.91B 11.8B 4.59B 49.02B 4.67B 4.57B
Net income	12.18B 84.61M 73.19M 68.68M 62.24M 115M 7.28B 130M 803M 312M 3.33B 318M 311M	14.75B 102M 88.64M 83.17M 75.37M 139M 8.82B 157M 972M 378M 4.04B 385M 376M
Net Debt	-58.1B -404M -349M -328M -297M -548M -34.74B -620M -3.83B -1.49B -15.9B -1.51B -1.48B	-65.07B -452M -391M -367M -332M -614M -38.91B -694M -4.29B -1.67B -17.81B -1.7B -1.66B